$PSTX
Poseida Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022029141 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $116.3M $2.700M $1.435M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.389M $9.237M $9.546M
YoY Change 3.56% 4.13% 14.05%
% of Gross Profit
Research & Development $35.14M $35.01M $40.75M
YoY Change 8.03% -2.78% 40.03%
% of Gross Profit
Depreciation & Amortization $1.350M $1.260M $1.207M
YoY Change 15.48% 11.5% 12.8%
% of Gross Profit
Operating Expenses $44.53M $44.25M $50.30M
YoY Change 7.06% -1.41% 34.25%
Operating Profit $71.78M -$41.55M -$56.96M
YoY Change -272.59% -7.43% 52.04%
Interest Expense $1.775M $1.543M -$1.077M
YoY Change 112.07% 83.04% -228.52%
% of Operating Profit 2.47%
Other Income/Expense, Net $656.0K $52.00K -$19.00K
YoY Change 21766.67% 205.88% 58.33%
Pretax Income $70.66M -$43.04M -$58.06M
YoY Change -266.56% -5.84% 51.53%
Income Tax $300.0K $0.00 $0.00
% Of Pretax Income 0.42%
Net Earnings $70.41M -$43.04M -$58.06M
YoY Change -265.97% -5.84% 51.53%
Net Earnings / Revenue 60.54% -1593.93% -4045.78%
Basic Earnings Per Share $0.92 -$0.69 -$0.93
Diluted Earnings Per Share $0.92 -$0.69 -$928.1K
COMMON SHARES
Basic Shares Outstanding 85.78M 62.71M 62.56M
Diluted Shares Outstanding 76.69M 62.71M 62.56M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $279.0M $142.6M $183.5M
YoY Change 41.04% -39.92% -32.04%
Cash & Equivalents $164.8M $62.96M $183.5M
Short-Term Investments $114.2M $79.59M
Other Short-Term Assets $7.677M $5.330M $7.021M
YoY Change 9.86% 71.33% 75.53%
Inventory
Prepaid Expenses
Receivables $38.47M $232.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $325.1M $148.1M $190.5M
YoY Change 58.76% -38.38% -30.47%
LONG-TERM ASSETS
Property, Plant & Equipment $21.75M $22.76M $22.10M
YoY Change -3.09% -2.32% -55.97%
Goodwill $4.228M $4.228M $4.228M
YoY Change
Intangibles $1.320M $1.320M $1.320M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.056M $1.051M $1.046M
YoY Change -73.34% -72.53% -70.94%
Total Long-Term Assets $55.35M $57.34M $57.64M
YoY Change -3.13% -2.39% -2.8%
TOTAL ASSETS
Total Short-Term Assets $325.1M $148.1M $190.5M
Total Long-Term Assets $55.35M $57.34M $57.64M
Total Assets $380.5M $205.5M $248.2M
YoY Change 45.26% -31.31% -25.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.426M $3.661M $3.589M
YoY Change -5.98% -18.75% 43.56%
Accrued Expenses $25.34M $31.62M $32.91M
YoY Change -0.1% 23.88% 61.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.97M $40.09M $43.92M
YoY Change 54.0% 25.29% 57.98%
LONG-TERM LIABILITIES
Long-Term Debt $58.16M $58.07M $57.97M
YoY Change 98.41% 98.36% 121.25%
Other Long-Term Liabilities $1.970M $1.836M $42.51M
YoY Change -96.11% -96.41% -17.93%
Total Long-Term Liabilities $60.13M $59.90M $100.5M
YoY Change 105.13% -25.57% 28.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.97M $40.09M $43.92M
Total Long-Term Liabilities $60.13M $59.90M $100.5M
Total Liabilities $164.2M $139.7M $144.5M
YoY Change 46.87% 24.1% 36.4%
SHAREHOLDERS EQUITY
Retained Earnings -$437.5M -$508.0M -$464.9M
YoY Change 7.15% 38.84%
Common Stock $654.0M $573.9M
YoY Change 17.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $216.3M $65.80M $103.7M
YoY Change
Total Liabilities & Shareholders Equity $380.5M $205.5M $248.2M
YoY Change 45.26% -31.31% -25.55%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $70.41M -$43.04M -$58.06M
YoY Change -265.97% -5.84% 51.53%
Depreciation, Depletion And Amortization $1.350M $1.260M $1.207M
YoY Change 15.48% 11.5% 12.8%
Cash From Operating Activities $61.88M -$39.73M -$51.30M
YoY Change -251.39% 27.81% 31.35%
INVESTING ACTIVITIES
Capital Expenditures -$1.703M -$1.218M $743.0K
YoY Change 366.58% -22.72% 56.42%
Acquisitions
YoY Change
Other Investing Activities -$34.17M -$79.61M $0.00
YoY Change -191.12% -227.38% -100.0%
Cash From Investing Activities -$35.87M -$80.83M -$743.0K
YoY Change -196.6% -232.69% -100.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.84M 32.00K 29.23M
YoY Change 3988.3% -52.24% 8019.72%
NET CHANGE
Cash From Operating Activities 61.88M -39.73M -51.30M
Cash From Investing Activities -35.87M -80.83M -743.0K
Cash From Financing Activities 75.84M 32.00K 29.23M
Net Change In Cash 101.8M -120.5M -22.84M
YoY Change -5511.48% -503.14% -126.61%
FREE CASH FLOW
Cash From Operating Activities $61.88M -$39.73M -$51.30M
Capital Expenditures -$1.703M -$1.218M $743.0K
Free Cash Flow $63.58M -$38.51M -$52.04M
YoY Change -256.96% 30.51% 31.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
156211000
us-gaap Interest Paid Net
InterestPaidNet
1996000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62713363
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62150961
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.029
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43036000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-45705000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43168000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45719000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62713363
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62150961
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
681000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4867000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-58057000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
103702000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
32000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5234000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43036000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
65800000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
261968000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
360000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
67000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4742000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-45705000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
186576000
us-gaap Profit Loss
ProfitLoss
-101093000
us-gaap Profit Loss
ProfitLoss
-84019000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2467000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
pstx Deferred Revenue In Operating Activities
DeferredRevenueInOperatingActivities
3903000
us-gaap Loss On Contract Termination
LossOnContractTermination
5687000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-205000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-5000
us-gaap Share Based Compensation
ShareBasedCompensation
10101000
us-gaap Share Based Compensation
ShareBasedCompensation
8204000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-405000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-332000
pstx Accretion Of Investment Discount Net
AccretionOfInvestmentDiscountNet
97000
pstx Accretion Of Investment Discount Net
AccretionOfInvestmentDiscountNet
-114000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
232000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1017000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1733000
pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
2262000
pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
1817000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-610000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
208000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5859000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3727000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-205000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2694000
pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2418000
pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1355000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91053000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70144000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1961000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2056000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
79611000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
187500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81572000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
185444000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
713000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
427000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1450000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
30000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29263000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
427000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-143362000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
115727000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
206325000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
83966000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62963000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
199693000
pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
1429000
pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
109000
us-gaap Interest Paid Net
InterestPaidNet
1356000
us-gaap Net Income Loss
NetIncomeLoss
-101100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91100000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-508000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, which include, but are not limited to, estimates related to revenue, accrued expenses, research and development expenses, stock-based compensation expense and deferred tax valuation allowances. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. </p>
pstx Number Of Reportable Segment
NumberOfReportableSegment
1
pstx Number Of Customer
NumberOfCustomer
1
us-gaap Variable Lease Payment
VariableLeasePayment
0
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
Payment terms on invoiced amounts are typically 30 - 60 days.
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
34237000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31187000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11481000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9137000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22756000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22050000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2500000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
CY2022Q2 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
14439000
CY2021Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
12292000
CY2022Q2 pstx Accrued Loss On Contract Termination
AccruedLossOnContractTermination
4493000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6001000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8760000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3766000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2488000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
28699000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23540000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
121348000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
132000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
121216000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
176102000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
176102000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1900000
CY2022Q2 pstx Debt Instrument Final Payment Fee Accrued
DebtInstrumentFinalPaymentFeeAccrued
1800000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2022Q2 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9899707
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3448889
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.75
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
47303
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
723068
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.48
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12578225
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.06
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
331000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12578225
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.06
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
331000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4273115
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.81
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
198000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
58000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2600000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3200000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
600000
us-gaap Operating Lease Payments
OperatingLeasePayments
3900000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5234000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4742000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10101000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8204000
CY2022Q2 us-gaap Area Of Land
AreaOfLand
110000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4400000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain of the Company’s manufacturing, laboratory and office space lease agreements include two options to extend the term for a period of five years each.
pstx Lessee Operating Lease Number Of Options To Extend Term
LesseeOperatingLeaseNumberOfOptionsToExtendTerm
2
CY2022Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3451000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7057000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6188000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6374000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5107000
CY2022Q2 pstx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16260000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
44437000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10948000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
33489000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6686000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26803000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15015753
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9137788

Files In Submission

Name View Source Status
0001564590-22-029141-index-headers.html Edgar Link pending
0001564590-22-029141-index.html Edgar Link pending
0001564590-22-029141.txt Edgar Link pending
0001564590-22-029141-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pstx-10q_20220630.htm Edgar Link pending
pstx-20220630.xsd Edgar Link pending
pstx-ex101_369.htm Edgar Link pending
pstx-ex311_7.htm Edgar Link pending
pstx-ex312_9.htm Edgar Link pending
pstx-ex321_6.htm Edgar Link pending
pstx-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
pstx-20220630_cal.xml Edgar Link unprocessable
pstx-20220630_def.xml Edgar Link unprocessable
pstx-20220630_pre.xml Edgar Link unprocessable
pstx-20220630_lab.xml Edgar Link unprocessable
pstx-10q_20220630_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable